“I would like to welcome Dr. Gómez de la Torre Pretell to the Arkstone team. His breadth of experience in clinical pathology and molecular diagnostics is an invaluable asset to our team,” said Ari Frenkel MD, Chief Science Officer and Co-founder of Arkstone, “We look forward to his leadership as we work towards our continued advancements.”
Dr. Gómez de la Torre Pretell, received his medical degree from the Catholic University of Santa María, and completed his Medical Internship at the Honorio Delgado Regional Hospital and the Urban Marginal Health Service (SERUMS) at the Peruvian Air Force Hospital in Iquitos. He completed the specialty of Clinical Pathology at the Federico Villarreal National University. He also graduated with a Master’s Degree in Molecular Biology from the Faculty of Biological Sciences of the Universidad Nacional Mayor de San Marcos and has a subspecialty in Infectious and Tropical Disease Medicine. In addition, he has a Master’s of Business Administration. Dr. Gómez de la Torre Pretell is an experienced university professor in different faculties of medicine and served as head of a laboratory. In 2004 he founded the Peruvian Institute of Molecular Biology (IPBM), continuing his activities in the Roe Clinical Laboratory as head of Molecular Biology, where he currently holds the position of Deputy Medical Director. He is the co-author of Molecular diagnostics of Infectious Disease, latest edition published in July 2016.
As a provider who has used the OneChoice Report in clinical practice, Dr. Gómez de la Torre Pretell has seen firsthand how Arkstone technology bridges the gap between advancements in infectious disease diagnostics and healthcare providers’ understanding. His insight and real-world experience will help to enhance how Arkstone disseminates clinically applicable information in a meaningful and actionable way.
Arkstone is committed to stem the global spread of antimicrobial resistance and the misuse of antibiotics by marrying advanced artificial intelligence with a deep understanding of infectious disease. Arkstone’s patent-pending OneChoice technology helps physicians practice precision-guided medicine through optimal treatment regimen recommendations. Additionally, the proprietary ArkScore system allows providers to compare antibiotics at a glance through an easy to understand visual score. Learn more at www.arkstonemedical.com or email email@example.com